...
首页> 外文期刊>Cancer Cell >Intratumor Heterogeneity: The Rosetta Stone of Therapy Resistance
【24h】

Intratumor Heterogeneity: The Rosetta Stone of Therapy Resistance

机译:肠内异质性:治疗抗性的玫瑰花之石

获取原文
获取原文并翻译 | 示例
           

摘要

Advances in our understanding of molecular mechanisms of tumorigenesis have translated into knowledge-based therapies directed against specific oncogenic signaling targets. These therapies often induce dramatic responses in susceptible tumors. Unfortunately, most advanced cancers, including those with robust initial responses, eventually acquire resistance to targeted therapies and relapse. Even though immune-based therapies are more likely to achieve complete cures, acquired resistance remains an obstacle to their success as well. Acquired resistance is the direct consequence of pre-existing intratumor heterogeneity and ongoing diversification during therapy, which enables some tumor cells to survive treatment and facilitates the development of new therapy-resistant phenotypes. In this review, we discuss the sources of intratumor heterogeneity and approaches to capture and account for it during clinical decision making. Finally, we outline potential strategies to improve therapeutic outcomes by directly targeting intratumor heterogeneity.
机译:我们对肿瘤发生分子机制的理解进展已转化为针对特异性致癌信号靶标的基于知识的疗法。这些疗法经常在易感肿瘤中诱导戏剧性的反应。不幸的是,最先进的癌症,包括具有稳健初始反应的癌症,最终获得对目标疗法和复发的抵抗力。尽管基于免疫的疗法更有可能实现完全的治疗,但获得的阻力仍然是他们成功的障碍。获得性阻力是预先存在的肿瘤内异质性和治疗期间持续多样化的直接后果,这使得一些肿瘤细胞能够存活并促进新的治疗抗性表型的发展。在这篇综述中,我们讨论了临床决策期间捕获和占据其捕获和占据的方法的毒品的来源。最后,我们通过直接针对腹腔内的异质性来概述潜在的策略来改善治疗结果。

著录项

  • 来源
    《Cancer Cell》 |2020年第4期|共14页
  • 作者单位

    H Lee Moffitt Canc Ctr &

    Res Inst Dept Canc Physiol Tampa FL 33612 USA;

    Scripps Res Inst Dept Mol Med Jupiter FL 33458 USA;

    Dana Farber Canc Inst Dept Med Oncol Boston MA 02215 USA;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 肿瘤学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号